Zymeworks to Spotlight Pipeline and Portfolio at Series of Major Healthcare Investor Conferences
at www.tipranks.com (Tue, 27-Jan 6:38 AM)
Zymeworks’ Phase 3 Results Point to Ziihera as Potential New Standard of Care in HER2-Positive GEA
Market Chameleon (Mon, 17-Nov 10:31 AM)
Ziihera Achieves Landmark Phase 3 Results, Paving Way for New HER2-Positive GEA Treatment Standard
Market Chameleon (Mon, 17-Nov 7:06 AM)
